Background: The high blood pressure (BP) or hypertension is a widely prevalent disease and its costs are very high, and many studies about the relationships between BP and health conditions have been done. We need to know the precise distributions of BP and factors affecting BP. Data and Methods : The distributions of BP are analyzed using 12,877,653 observations obtained from the JMDC Claims Database. The factors that may affect the BP are analyzed by the regression models using 4,615,346 observations. Results: The averages of systolic BP (SBP) and diastolic BP (DBP) are 120.4 and 74.2 mmHg with standard deviations of 15.9 and 11.3 mmHg, respectively. Among the nonmodifiable factors, age and gender are important factors. Among the modifiable factors, variables related to obesity are important risk factors. Taking antihypertensive drugs makes SBP and DBP 13.4 mmHg and 7.8 mmHg lower. Conclusion: The criteria of BP should be carefully determined considering age and gender. The effects of age may be a little different for SBP and DBP. It is necessary to use the proper model to evaluate the effect of antihypertensive drugs correctly. Limitations: The dataset is observatory. Although there are various types of treatment methods and antihypertension drugs, their effects are not evaluated.
KeywordsBlood PressureHypertensionSBP and DBPMedical CheckupsAntihypertensive Drugs
World Health Organization (2020) World Health Statistics 2020: Monitoring Health for the SDGs, Sustainable Development Goals. World Health Organization, Geneva.
World Health Organization (2019) Hypertension. https://www.who.int/news-room/fact-sheets/detail/hypertension#:~:text=Hypertension%20%2D%20or%20 elevated%20blood%20pressure,%2D%20and%20middle%2Dincome%20countries
World Health Organization (2021) Raised Blood Pressure (SBP≥140 OR DBP≥90; Crude Estimate: Last Updated 2017-11-17). https://www.who.int/data/gho/data/indicators/indicator-details/GHO/raised-blood-pressure-(sbp-=140-or-dbp-=90)-(crude-estimate)
Benjamin, E.J., Virani, S.S., Callaway, C.W., Chamberlain, A.M., Chang, A.R., Cheng, S., et al. (2018) Heart Disease and Stroke Statistics—2018 Update: A Report from the American Heart Association. Circulation, 137, e67-e492. https://doi.org/10.1161/CIR.0000000000000558
Blood Pressure UK (2020) The Blood Pressure Chart. http://www.bloodpressureuk.org/your-blood-pressure/understanding-your-blood-pressure/what-do-the-numbers-mean/
Whelton, P.K., Carey, R.M., Arrow, W.S. Casey, D.E., Collins, K.J., Himmelfarb, C.D., et al. (Writing Committee Members) (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71, e13-e115. https://doi.org/10.1161/HYP.0000000000000065
Whelton, P.K., Carey, R.M., Arrow, W.S., et al. (2018) 2017 Guideline for Blood Pressure in Adults. American College of Cardiology, Washington DC. http://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/11/09/11/41/2017-guideline-for-high-blood-pressure-in-adults
Carey, R.M. and Whelton P.K. for the 2017 ACC/AHA Hypertension GuidelineWriting Committee (2018) Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Annals of Internal Medicine, 168, 351-335. https://doi.org/10.7326/M17-3203
Center for Disease Control and Prevention (2020) Facts about Hypertension. https://www.cdc.gov/bloodpressure/facts.htm
Ostchega, Y., Fryar, C.D., Nwankwo, T. and Nguyen, D.T. (2020) Hypertension Prevalence among Adults Aged 18 and Over: United States, 2017-2018. NCHS Data Brief, No. 364, 1-8.
American Diabetes Association (2018) Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018. Diabetes Care, 41, S86-S104. https://doi.org/10.2337/dc18-S009
LeFevre, M. (2018) ACC/AHA Hypertension Guideline: What is New? What Do We Do? American Family of Physician, 97, 372-373.
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., et al. (2018) 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. European Heart Journal, 39, 3021-3104. https://doi.org/10.1093/eurheartj/ehy339
Nerenberg, K.A., Zarnke, K.B., Leung, A.A., Dasgupta, K., Butalia, S., McBrien, K., et al. (2018) Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 34, 506-525. https://doi.org/10.1016/j.cjca.2018.02.022
Goupil, R., Lamarre-Cliché, M. and Vallee, M. (2018) The 2017 American College of Cardiology/American Heart Association vs Hypertension Canada High Blood Pressure Guidelines and Potential Implications. Canadian Journal of Cardiology, 34, 665-669. https://doi.org/10.1016/j.cjca.2018.01.011
Hirawa, N., Umemura, S. and Ito, S. (2019) Viewpoint on Guidelines for Treatment of Hypertension in Japan. Circulation Research, 124, 981-983. https://doi.org/10.1161/CIRCRESAHA.119.314991
Ministry of Health, Labour and Welfare (2019) Heisei 29 nenkanjashosa no gayou (Summary of the Patient Survey in 2017). Ministry of Health, Labour and Welfare, Tokyo. (In Japanese)
Ministry of Health, Labour and Welfare (2020) Heisei 30 nendokokuminiryouhi no gayou (Summary of National Medical Expenditures in Fiscal Year 2018). Ministry of Health, Labour and Welfare, Tokyo. (In Japanese)
Boston University and National Heart, Lung, & Blood Institute (2021) Framingham Heart Study. https://www.framinghamheartstudy.org
Joffres, M.R., Mamet, P., MacLean, D.R., L’italien, G.J. and Fodor, G. (2001) Distribution of Blood Pressure and Hypertension in Canada and the United States. American. Journal of Hypertension, 14, 1099-1105. https://doi.org/10.1016/S0895-7061(01)02211-7
Prospective Studies Collaboration (2002) Age-Specific Relevance of Usual Blood Pressure to Vascular Mortality: A Meta-Analysis of Individual Data for One Million Adults in 61 Prospective Studies. Lancet, 360, 1903-1913. https://doi.org/10.1016/S0140-6736(02)11911-8
Rapsomaniki, E., Timmis, A., George, J., Pujades-Rodriguez, M., Shah, A.D., Denaxas, S., et al. (2014) Blood Pressure and Incidence of Twelve Cardiovascular Diseases: Lifetime Risks, Healthy Life-Years Lost, and Age-Specific Associations in 1.25 Million People. Lancet, 383, 1899-1911. https://doi.org/10.1016/S0140-6736(14)60685-1
The SPRINT Research Group (2015) A Randomized Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine, 373, 2103-2116. https://doi.org/10.1056/NEJMoa1511939
The ACCORD Study Group (2010) Effect of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine, 362, 1575-1585. https://doi.org/10.1056/NEJMoa1001286
Ettehad, D., Emdin, C.A., Kiran, A., Anderson, S.G., Callender, T., Emberson, J., et al. (2016) Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: A Systematic Review and Meta-analysis. Lancet, 387, 957-967. https://doi.org/10.1016/S0140-6736(15)01225-8
Muntner, P., Carey, R.M., Gidding, S., Jones, D.W., Taler, S.J., Wright Jr., J.T., et al. (2018) Potential U.S. Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Journal of the American College of Cardiology, 71, 109-118. https://doi.org/10.1016/j.jacc.2017.10.073
Ministry of Health, Labour and Welfare (2020) National Health and Nutrition Survey in Japan, 2019. Ministry of Health, Labour and Welfare, Tokyo. (In Japanese)
Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University (2021) Higayama Study. http://www.hisayama.med.kyushu-u.ac.jp/en/
Honda, T., Yoshida, D., Hata, J., Hirakawa, Y., Ishida, Y., Shibata, M., et al. (2018) Development and Validation of Modified Risk Prediction Models for Cardiovascular Disease and its Subtypes: The Hisayama Study. Atherosclerosis, 279, 38-44. https://doi.org/10.1016/j.atherosclerosis.2018.10.014
Fujiyoshi, A., Ohkubo, T., Miura, K., Murakami, Y., Nagasawa, S., Okamura, T., et al. (2012) Blood Pressure Categories and Log-term Risk of Cardio-vascular Disease According to Age Group in Japanese Men and Women. Hypertension Research, 35, 947-953. https://doi.org/10.1038/hr.2012.87
Asayama, K., Satoh, M., Murakami, Y., Ohkubo, T., Nagasawa, S., Tsuji, I., et al. (2014) Cardiovascular Risk with and without Antihypertensive Drug Treatment in the Japanese General Population Participant-Level Meta-Analysis. Hypertension, 63, 1189-1197. https://doi.org/10.1161/HYPERTENSIONAHA.113.03206
Nawata, K., Matsumoto, A., Kajihara, R. and Kimura, M. (2017) Evaluation of the Distribution and Factors Affecting Blood Pressure Using Medical Checkup Data in Japan. Health, 9, 124-137. https://doi.org/10.4236/health.2017.91009
Nawata, K. and Kimura, M. (2017). Reliability of Blood Pressure Measurements: An Analysis of the White Coat Effect and its Fluctuations. Health, 9, 506-519. https://doi.org/10.4236/health.2017.93036
Nawata, K., Sekizawa, Y. and Kimura, M. (2018) Evaluation of Blood Pressure Control Medicines using Health and Medical Checkup Data in Japan: Alternative Methods for Randomized Controlled Trials. Health, 10, 587-603. https://doi.org/10.4236/health.2018.105047
Yu, J., Wei, Y., Jing, Y. and Gao, Y. (2021) Effect of Acupuncture on Essential Hypertension: A Protocol for Systematic Review and Meta-Analysis. Medicine, 100, e25572. https://doi.org/10.1097/MD.0000000000025572
Nawata, K. and Kimura, M. (2018) Does High Systolic Blood Pressure Truly Increase Medical Expenditure? An Empirical Analysis of the New 2017 ACC/AHA Hypertension Guideline. Health, 10, 1044-1065. https://doi.org/10.4236/health.2018.108079
Nawata, K. and Kimura, M. (2018) Empirical Studies of Effects of High Blood Pressure on Medical Costs and Heart Disease: Is the 2017 ACC/AHA Guideline Supported by Enough Evidence? Health, 10, 1498-1519. https://doi.org/10.4236/health.2018.1011115
Nawata, K., Sugano, H. and Kimura, M. (2019) An Analysis of the Effects of Blood Pressure and Antihypertensive Drugs on Heart Disease. Health, 11, 792-816. https://doi.org/10.4236/health.2019.116064
Nawata, K. (2020) Risk Factors Affecting Ischemic Stroke: Potential Side Effect of Antihypertensive Drugs. Health, 12, 437-455. https://doi.org/10.4236/health.2020.125035
Kaneko, H., Yano, Y., Ito, H., Morita, K., Kiriyama, H., Kamon, T., et al. (2021) Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline with Risk of Heart Failure and Atrial Fibrillation. Circulation, 143, 2244-2253. https://doi.org/10.1161/CIRCULATIONAHA.120.052624
Akbay, E., Coner, A., Akinci, S., Riza Demir, A. and Toktamis, A. (2021) Which Is Responsible for Target Organ Damage in Masked Hypertension? Is It an Increase in Blood Pressure or a Disruption of the Circadian Rhythm? Clinical and Experimental Hypertension, 18, 1-7. https://doi.org/10.1080/10641963.2021.1916946
U.S. National Library of Medicine (2021) High Blood Pressure Medicines. https://medlineplus.gov/ency/article/007484.htm
Li, W., Moore, M.J., Vasilieva, N., Sui, J., Wong, S.K., Berne, M.A., et al. (2003) Angiotensin-Converting Enzyme 2 Is a Functional Receptor for the SARS Coronavirus. Nature, 426, 450-454. https://doi.org/10.1038/nature02145
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., et al. (2005) A Crucial Role of Angiotensin Converting Enzyme 2 (ACE2) in SARS Coronavirus-Induced Lung Injury. Nature Medicine, 11, 875-879. https://doi.org/10.1038/nm1267
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181, 271-280.E8. https://doi.org/10.1016/j.cell.2020.02.052
Bourgonje, A.R., Abdulle, A.E., Timens, W., Hillebrands, J.-L., Navis, G.J., Gordijn, S.J., et al. (2020) Angiotensin-Converting Enzyme 2 (ACE2), SARS-CoV-2 and the Pathophysiology of Coronavirus Disease 2019 (COVID-19). Journal of Pathology, 251, 228-248. https://doi.org/10.1002/path.5471
European Medicines Agency (EMA) (2020) Latest Data Support Continued Use of ACE Inhibitors and ARB Medicines during COVID-19 Pandemic. https://www.ema.europa.eu/en/news/latest-data-support-continued-use-ace-inhibitors-arb-medicines-during-covid-19-pandemic
World Health Organization (2020) COVID-19 and the Use of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers. https://www.who.int/news-room/commentaries/detail/covid-19-and-the-use-of-angiotensin-converting-enzyme-inhibitors-and-receptor-blockers
Bozkurt, B., Kovacs, R. and Harrington, B. (2020) HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. American College of Cardiology, Washington DC. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19
Emilsson, V., Gudmundsson, F.E., Aspelund, T., Jonsson, B.G., Gudjonsson, A., Launer, L.J., et al. (2020) Antihypertensive Medication Uses and Serum ACE2 Levels ACEIs/ARBs Treatment Does Not Raise Serum Levels of ACE2. medRxiv. (Preprint) https://doi.org/10.1101/2020.05.21.20108738
Fang, L., Karakiulakis, G. and Roth, M. (2020) Are Patients with Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection? Lancet Respiratory Medicine, 8, e21. https://doi.org/10.1016/S2213-2600(20)30116-8
Zhang, H., Penninger, J.M., Li, Y., Zhong, N. and Slutsky, A.S. (2020) Angiotensin-Converting Enzyme 2 (ACE2) as a SARS-CoV-2 Receptor: Molecular Mechanisms and Potential Therapeutic Target. Intensive Care Medicine, 46, 586-590. https://doi.org/10.1007/s00134-020-05985-9
Gao, C., Cai, Y., Zhang, K., Zhou, L., Zhang, Y., Zhang, X., et al. (2020) Association of Hypertension and Antihypertensive Treatment with COVID-19 Mortality: A Retrospective Observational Study. European Heart Journal, 41, 2058-2066. https://doi.org/10.1093/eurheartj/ehaa433
Gracia-Ramos, A.E. (2020) Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection? Archives of Medical Research, 51, 345-346. https://doi.org/10.1016/j.arcmed.2020.03.011
Gurwitz. D. (2020) Angiotensin Receptor Blockers as Tentative SARS-CoV-2 Therapeutics. Drug Development Search, 81, 537-540. https://doi.org/10.1002/ddr.21656
Kreutz, R., Algharably, E.A.E., Azizi, M., Dobrowolski, P., Guzik, T., Januszewicz, A., et al. (2020) Hypertension, the Renin-Angiotensin System, and the Risk of Lower Respiratory Tract Infections and Lung Injury: Implications for COVID-19. Cardiovascular Research, 116, 1688-1699. https://doi.org/10.1093/cvr/cvaa097
Lee, I.T., Nakayama, T., Wu, C., Goltsev, Y., Jiang, S., Gall, P.A., et al. (2020) ACE2 Localizes to the Respiratory Cilia and is not Increased by ACE Inhibitors or ARBs. Nature Communications, 11, Article No. 5453. https://doi.org/10.1038/s41467-020-19145-6
Liu, M., Wang, T., Zhou, Y., Zhao, Y., Zhang, Y. and Li, J. (2020) Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management. Journal of Internal Medicine, 8, 9-19. https://doi.org/10.2478/jtim-2020-0003
Mourad, J. and Levy, B.I. (2020) Interaction between RAAS Inhibitors and ACE2 in the Context of COVID-19. Nature Reviews of Cardiology, 17, 313. https://doi.org/10.1038/s41569-020-0368-x
Ryan, J.J., Melendres-Groves, L., Zamanian, R.T., Oudiz, R.J., Chakinala, M., Rosenzweig, E.B., et al. (2020) Patients with Pulmonary Arterial Hypertension during the Coronavirus (COVID-19) Pandemic. Pulmonary Circulation, 10, 1-7. https://doi.org/10.1177%2F2045894020920153
Schiffrin, E.L., Flack, J.M., Ito, S., Muntner, P. and Clinton Webb, R. (2020) Hypertension and COVID-19. American Journal of Hypertension, 33, 373-374. https://doi.org/10.1093/ajh/hpaa057
Sriram, K. and Insel, P.A. (2020) Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence. Clinical Pharmacology & Therapeutics, 108, 236-241. https://doi.org/10.1002/cpt.1863
Tignanelli, C.J., Ingraham, N.E., Sparks, M.A., Reilkoff, R., Bezdicek, T., Benson, B., et al. (2020) Antihypertensive Drugs and Risk of COVID-19? Lancet Respiratory Medicine, 8, e30-e31. https://doi.org/10.1016/S2213-2600(20)30153-3
Wysocki, J., Lores. E., Ye, M., Soler, M.J. and Batlle, D. (2020) Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. Journal of American Society of Nephrology, 31, 1941-1943. https://doi.org/10.1681/ASN.2020050667
Zheng, Y., Ma, Y., Zhang, J. and Xie, X. (2020) COVID-19 and the Cardiovascular System. Nature Reviews Cardiology, 17, 259-260. https://doi.org/10.1038/s41569-020-0360-5
Bonner, C., Cvejic, E., Ayre, J., Isautier, J., Semsarian, C., Nickel, B., et al. (2021) The Psychological Impact of Hypertension During COVID-19 Restrictions: Retrospective Case-Control Study. JMIRx Med, 2, e25610. https://doi.org/10.2196/25610
Bottinoa, L.G. and Fuchsa, F.D. (2021) Response to the letter to the editor entitled “Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic.” Expert Review of Cardiovascular Therapy, 19, 189-190. https://doi.org/10.1080/14779072.2021.1862548
Hosseinzadeh, R., Goharrizi, M.A.S., Bahardoust, M., Ghorbani Alvanegh, A., Reza Ataee, M., Bagheri, M., et al. (2021) Should All Patients with Hypertension Be Worried about Developing Severe Coronavirus Disease 2019 (COVID-19)? Clinical Hypertension, 27, Article No. 3. https://doi.org/10.1186/s40885-021-00161-7
Miyazawa, D. (2021) Why Obesity, Hypertension, Diabetes, and Ethnicities Are Common Risk Factors for COVID-19 and H1N1 Influenza Infections. Journal of Medical Virology, 93, 127-128. https://doi.org/10.1002/jmv.26220
White, H. (1980). A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity. Econometrica, 48, 817-838. https://doi.org/10.2307/1912934
Miura, K., Nagai, M. and Ohkubo, T. (2013) Epidemiology of Hypertension in Japan: Where are We Now? Circulation Journal, 77, 2226-2231.
Chobanian, A.V., Bakris, G.L., Black, H.B., Cushman, W.C., Green, L.A., Izzo Jr., J.L., et al. (2003) Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206-1252. https://doi.org/10.1161/01.HYP.0000107251.49515.c2